Certain reflux and ulcer medications linked with bone fractures in dialysis patients

Certain reflux and ulcer medications linked with bone fractures in dialysis patients

A dose-response gastric secretion test was also performed. The frequency of Helicobacter-positive subjects was low (15/89, 17%), corresponding to figures reported in the literature for young symptomless volunteers. Helicobacter-positive patients had significantly more frequently upper gastrointestinal symptoms than Helicobacter-negative individuals (P less than 0.05).

Use of acid suppressive therapy

CKD5-ND patients also suffered from poorer appetite compared to ESRD patients, likely from uncorrected uremia and poorer psychosocial mental state (usually arising from anxiety from having to start dialysis soon). Like the dialysis population, CKD5-ND patients experienced more overall GI symptoms and had poorer appetite than controls.

In both groups, researchers associated use of the drugs with an increased risk of chronic kidney disease over 10 years. Methods. A total of 293 patients with CRF were compared with 261 hospitalized patients and 181 patients with another chronic disease. Information about AST, endoscopic investigations and indication for therapy were obtained by medical records and patient interviews.

Impact of dialysis on gastroesophageal reflux, dyspepsia, and proton pump inhibitor treatment in patients with chronic renal failure

Gastrointestinal (GI ) symptoms are proven to be more common in patients undergoing peritoneal dialysis than in patients with chronic renal failure having hemodialysis. However, whether the onset of these GI symptoms is related to the chronic renal failure itself, its treatment, or alternatively, other factors, is still unknown. These symptoms may mean you have acid reflux and heartburn, which can usually be relieved by antacids and no medical treatment.

  • World Journal of Gastroenterology.
  • In such cases, dialysis or a kidney transplant is needed to keep patients alive.
  • in a muscle between the esophagus and stomach.
  • This does not mean that everyone who uses PPIs will get chronic kidney disease, but it is important to know that there may be a risk.

National Institutes of Health. Gastroesophageal reflux disease (GERD) is a relatively common symptom in peritoneal dialysis (PD) patients(1-3).

World Journal of Gastroenterology. “What affects the gastrointestinal symptoms in peritoneal dialysis patients?.” ScienceDaily. ScienceDaily, 24 June 2010. It has not been proven that PPI use causes chronic kidney disease, but some studies suggest there is an increased risk of chronic kidney disease in individuals who have normal kidney function before using a PPI.

The evidence for increased mortality was similar in both PD [21] and HD [22] patients. The study also revealed that poor appetite was not limited to dialysis patients as CKD5-ND patients also displayed similar anorexic symptoms, consistent with other studies published [23]. Another study reported that poor appetite affected survival in PD patients but not CKD5-ND patients [24].

Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects.

dialysis and acid reflux

Leave a Comment

Your email address will not be published. Required fields are marked *